Sagimet Biosciences Income Statement (2023-2024) | SGMT

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024
Revenue & cost
Revenue 2.00M
Operating items
Research & Development 4.96M5.66M
Selling, General & Administrative 4.49M3.81M
Operating Expenses 9.45M9.47M
Operating Income -7.45M-9.47M
EBIT -7.45M-9.47M
Non-operating items
Interest & Investment Income 1.09M1.31M
Other Non Operating Income 1.10M1.31M
Non Operating Income 1.10M1.31M
Net income details
EBT -6.36M-8.15M
Profit After Tax -6.35M-8.15M
Income from Continuing Operations -6.36M-8.15M
Consolidated Net Income -6.36M-8.15M
Income towards Parent Company -6.36M-8.15M
Net Income towards Common Stockholders -6.36M-8.15M
Additional items
EPS (Basic) -0.350.56
EPS (Weighted Average and Diluted) -0.350.56
Shares Outstanding (Weighted Average) 16.86M22.88M22.90M31.91M31.91M32.20M
Shares Outstanding (Diluted Average) 0.19M0.19M18.19M10.46M29.04M31.91M32.14M
EBITDA -6.35M-8.12M